RxDoctor Payments Data

Jalean Heikenfeld, APRN

Nurse Practitioner · Greendale, INNPI 1093084774

Payments from drug & device makers

$8,344in general payments, 2019–2025

Across 486 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Medtronic$1K
  • Lilly USA, LLC$1K
  • Dexcom, Inc.$734
  • Abbott$648
  • Novartis$233
  • plus $3K from 43 others

What the payments were for

  • Travel & lodging$7419%
  • Food & beverage$7,56091%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,344 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$39,849
Medicare patients
157
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide260$426,828
MounjaroTirzepatide227$324,064
TrulicityDulaglutide164$244,336
JardianceEmpagliflozin185$222,571
Humulin R U-500 KwikpenInsulin Regular, Human31$132,356
Tresiba Flextouch U-100Insulin Degludec97$70,094
RybelsusSemaglutide35$63,978
FarxigaDapagliflozin Propanediol42$45,157
Fiasp FlextouchInsulin Aspart (Niacinamide)26$44,594
Lantus SolostarInsulin Glargine,hum.Rec.Anlog242$40,552
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog48$32,677
Novolog FlexpenInsulin Aspart88$31,582
Insulin Lispro Kwikpen U-100Insulin Lispro54$28,046
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$21,681
Humalog Kwikpen U-100Insulin Lispro48$21,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,189$573,984410 claims
Novo NordiskOzempic, Rybelsus, Novolog$1,503$495,206307 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$119$256,201236 claims
AstraZenecaFarxiga$50$45,15742 claims
AbbVieSynthroid$146$3,25247 claims
Sanofi-aventis U.S. LLCLantus$219$1,28012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Greendale

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →